214 related articles for article (PubMed ID: 37419144)
1. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Siegel SAR; Griffith DE; Philley JV; Brown-Elliott BA; Brunton AE; Sullivan PE; Fuss C; Strnad L; Wallace RJ; Winthrop KL
Chest; 2023 Oct; 164(4):846-859. PubMed ID: 37419144
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW
Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600
[TBL] [Abstract][Full Text] [Related]
3. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by
Griffith DE; Eagle G; Thomson R; Aksamit TR; Hasegawa N; Morimoto K; Addrizzo-Harris DJ; O'Donnell AE; Marras TK; Flume PA; Loebinger MR; Morgan L; Codecasa LR; Hill AT; Ruoss SJ; Yim JJ; Ringshausen FC; Field SK; Philley JV; Wallace RJ; van Ingen J; Coulter C; Nezamis J; Winthrop KL;
Am J Respir Crit Care Med; 2018 Dec; 198(12):1559-1569. PubMed ID: 30216086
[No Abstract] [Full Text] [Related]
4. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure.
Griffith DE; Thomson R; Flume PA; Aksamit TR; Field SK; Addrizzo-Harris DJ; Morimoto K; Hoefsloot W; Mange KC; Yuen DW; Ciesielska M; Wallace RJ; van Ingen J; Brown-Elliott BA; Coulter C; Winthrop KL;
Chest; 2021 Sep; 160(3):831-842. PubMed ID: 33887244
[TBL] [Abstract][Full Text] [Related]
5. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K
Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300
[TBL] [Abstract][Full Text] [Related]
6. Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
Jhun BW; Yang B; Moon SM; Lee H; Park HY; Jeon K; Kwon OJ; Ahn J; Moon IJ; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661870
[TBL] [Abstract][Full Text] [Related]
7. Amikacin Liposome Inhalation Suspension for
Winthrop KL; Flume PA; Thomson R; Mange KC; Yuen DW; Ciesielska M; Morimoto K; Ruoss SJ; Codecasa LR; Yim JJ; Marras TK; van Ingen J; Wallace RJ; Brown-Elliott BA; Coulter C; Griffith DE
Ann Am Thorac Soc; 2021 Jul; 18(7):1147-1157. PubMed ID: 33326356
[No Abstract] [Full Text] [Related]
8. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.
Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Mycobacterium abscessus Pulmonary Disease.
Griffith DE; Daley CL
Chest; 2022 Jan; 161(1):64-75. PubMed ID: 34314673
[TBL] [Abstract][Full Text] [Related]
10. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C
Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391
[TBL] [Abstract][Full Text] [Related]
11. The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults.
Khan O; Chaudary N
Drug Des Devel Ther; 2020; 14():2287-2294. PubMed ID: 32606598
[TBL] [Abstract][Full Text] [Related]
12. Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease.
Koh WJ; Jeong BH; Jeon K; Kim SY; Park KU; Park HY; Huh HJ; Ki CS; Lee NY; Lee SH; Kim CK; Daley CL; Shin SJ; Kim H; Kwon OJ
Chest; 2016 Dec; 150(6):1211-1221. PubMed ID: 27167209
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells.
Le Moigne V; Blouquit-Laye S; Desquesnes A; Girard-Misguich F; Herrmann JL
J Antimicrob Chemother; 2022 Nov; 77(12):3496-3503. PubMed ID: 36253948
[TBL] [Abstract][Full Text] [Related]
14. Clofazimine in
Pinapala A; Koh LJ; Ng KH; Tambyah PA; Yap HK
Perit Dial Int; 2021 Jan; 41(1):104-109. PubMed ID: 32148178
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.
Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N
BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679
[TBL] [Abstract][Full Text] [Related]
16. Rapid macrolide and amikacin resistance testing for
Bordin A; Pandey S; Coulter C; Syrmis M; Pardo C; Hackett H; Bell SC; Wainwright CE; Nimmo GR; Jennison AV; Clark JE; Whiley DM
J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33909552
[No Abstract] [Full Text] [Related]
17. Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease.
Choi H; Jhun BW; Kim SY; Kim DH; Lee H; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Diagn Microbiol Infect Dis; 2018 Apr; 90(4):293-295. PubMed ID: 29329759
[TBL] [Abstract][Full Text] [Related]
18. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
[TBL] [Abstract][Full Text] [Related]
19. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study.
Henriette Zweijpfenning SM; Chiron R; Essink S; Schildkraut J; Akkerman OW; Aliberti S; Altenburg J; Arets B; van Braeckel E; Delaere B; Gohy S; Haarman E; Lorent N; McKew G; Morgan L; Wagner D; van Ingen J; Hoefsloot W
Chest; 2022 Jul; 162(1):76-81. PubMed ID: 35063454
[No Abstract] [Full Text] [Related]
20. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.
Olivier KN; Griffith DE; Eagle G; McGinnis JP; Micioni L; Liu K; Daley CL; Winthrop KL; Ruoss S; Addrizzo-Harris DJ; Flume PA; Dorgan D; Salathe M; Brown-Elliott BA; Gupta R; Wallace RJ
Am J Respir Crit Care Med; 2017 Mar; 195(6):814-823. PubMed ID: 27748623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
